Clinical trials: Activation Proportion
NSCLC, Locally Advanced
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced…
- Trial name
- TRIPL (NCT06865339)
- Testing
- Cemiplimab, Fianlimab, Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Montefiore Medical Center
Digital Care-plan, Long-term Care
The Effectiveness of Digital Care-plan for Improving Long-term Care 2.0 Service Activation Proportion
Digital tools can potentially improve the public's reception to and understanding of long-term care information, which will be significantly helpful for long-term care workers and effectively increase the coverage provided by…
- Conditions
- Digital Care-plan, Long-term Care, Activation Proportion, Case Management, APP(Application)
- Trial name
- NCT05441735
- Testing
- APP
- Where
- Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Taipei University of Nursing and Health Sciences
Non Small Cell Lung Cancer
Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.
- Trial name
- MUTACT (NCT01167972)
- Where
- 101 sites in France
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca